Breaking news on life science and diagnostics business, policy, and funding
Sunquest and N-of-One are aiming to help pathologists create actionable, patient-specific genetic reports from NGS panels.
The test is designed to detect 14 of the most prevalent mutations in the gene responsible for the disease.
The groups will receive a combined $1 million to spend on educating their communities about precision medicine and the benefits of participating in All of Us.
The deal covers BioDiscovery's products, including the NxClinical 4.0 software system for genomic variant analysis and interpretation.
A lawyer and a scientist say the best result in the CRISPR patent fight would be narrow patents that prevent anyone from controlling downstream innovation.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.